Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

Drug Control Governance: Regulatory Bodies and Their Impact

Drug Control Governance: Regulatory Bodies and Their Impact

Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...

Drug Administration and Therapy Phases: Overview

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Drug Regulation

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Accelerating progress on essential medicines: a new Lancet Commission.

Lancet (London, England)·2025

Same author

Refocusing the World Health Organization's Model List of Essential Medicines on the needs of low and middle income countries.

BMJ (Clinical research ed.)·2024

Same author

Decision criteria for selecting essential medicines and their connection to guidelines: an interpretive descriptive qualitative interview study.

Journal of clinical epidemiology·2022

Same author

Why are certain age bands used for children in paediatric studies of medicines?

Archives of disease in childhood·2021

Same author

Availability, prices, and affordability of selected essential cancer medicines in a middle-income country - the case of Mexico.

BMC health services research·2020

Same author

Legislating for universal access to medicines: a rights-based cross-national comparison of UHC laws in 16 countries.

Health policy and planning·2019

Search research articles

Related Experiment Video

Updated: May 29, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Global aspects of drug development.

Kalle Hoppu¹, Hans V Hogerzeil

¹Poison Information Centre, Helsinki University Central Hospital and Hospital for Children and Adolescents, Institute for Clinical Sciences, University of Helsinki, Helsinki, Finland. kalle.hoppu@hus.fi

Handbook of Experimental Pharmacology

|September 2, 2011

Summary

Millions of children under five die annually from treatable conditions. Improving access to essential medicines for children globally is crucial for achieving child health goals and addressing developmental needs.

More Related Videos

An All-Human Hepatic Culture System for Drug Development Applications

An All-Human Hepatic Culture System for Drug Development Applications

Published on: October 20, 2023

Related Experiment Videos

Last Updated: May 29, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

An All-Human Hepatic Culture System for Drug Development Applications

An All-Human Hepatic Culture System for Drug Development Applications

Published on: October 20, 2023

Area of Science:

Child Health
Global Health
Pharmaceutical Development

Background:

Approximately nine million children under five die yearly from preventable or treatable conditions.
Lack of access to appropriate medicines is a significant, though not the sole, contributor to child mortality.
Existing medicines could prevent many of these deaths, highlighting a critical gap in healthcare access.

Purpose of the Study:

To explore the challenges and opportunities in developing pediatric medicines for the developing world.
To emphasize the importance of global and regional initiatives in pediatric medicine development.
To highlight tools and strategies for improving children's access to essential medicines.

Main Methods:

Review of global child mortality data related to treatable conditions.
Analysis of the role of existing medicines in pediatric healthcare.
Examination of regional and global initiatives for pediatric medicine development.
Case study of the World Health Organization's Essential Medicines List for children.

Main Results:

Many childhood deaths are preventable with existing, accessible medicines.
Global and regional collaborations can amplify the impact of pediatric medicine initiatives.
The Essential Medicines List for children is a key tool for improving access.

Conclusions:

Enhanced access to appropriate medicines is vital for achieving global child health targets.
Targeted development and distribution of pediatric medicines are essential for low-resource settings.
International cooperation and resource allocation are critical for pediatric pharmaceutical advancement.